Use of thiazolidinediones and risk of bladder cancer: Disease or drugs?

Current Drug Safety

Volumn 8, Issue 5, 2013, Pages 364-370

  Bazelier, Marloes T ^a   de Vries, Frank ^a,b,c   Vestergaard, Peter ^d   Leufkens, Hubert G M ^a   De Bruin, Marie L ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adverse events; Bladder cancer; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; INSULIN; SULFONYLUREA;

ADULT; ARTICLE; BLADDER CANCER; CANCER RISK; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETIC PATIENT; DRUG USE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; DENMARK; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84891554892     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748863113086660069     Document Type: Article

References (33)

1. Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us? Diabetes Obes Metab 2010; 12(12): 1023-35.
2. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49(17): 1772-80.
3. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362(18): 1675-85.
4. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009; 32: 187-202.
5. Suzuki S, Arnold LL, Pennington KL, et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci 2010; 113(2): 349-57.
6. Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer 2008; 123(10): 2254-9.
7. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34(4): 916-22.
8. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012; 35(2): 278-80.
9. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55(7): 1953-62.
10. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested casecontrol study. BMJ 2012; 344: e3645.
11. Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 2013; 75(1): 254-9.
12. Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 2012; 104(18): 1411-21.
13. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49(12): 2819-23.
14. Vairaktaris E, Goutzanis L, Yapijakis C, et al. Diabetes enhances the expression of H-ras and suppresses the expression of EGFR leading to increased cell proliferation. Histol Histopathol 2009; 24(5): 531-9.
15. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011; 54(8): 2009-15.
16. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register: A valuable source of data for modern health sciences. Dan Med Bull 1999; 46(3): 263-8.
17. Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen TD. The national patient registry: Evaluation of data quality. Ugeskr Laeger 1995; 157(26): 3741-5.
18. www.dkma.dk [Accessed June 29, 2011]
19. Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev 2007; 16(1): 83-9.
20. MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: evidence from a casecontrol study in New England. Cancer 2011; 117(7): 1552-6.
21. Larsson SC, Andersson SO, Johansson JE, Wolk A. Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. Eur J Cancer 2008; 44(17): 2655-60.
22. Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol 2006; 3(6): 327-40.
23. Reynolds K, Liese AD, Anderson AM, et al. Prevalence of tobacco use and association between cardiometabolic risk factors and cigarette smoking in youth with type 1 or type 2 diabetes mellitus. J Pediatr 2011; 158(4): 594-601.
24. Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 2003; 104(5): 597-602.
25. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999; 1(4): 330-9.
26. Plissonnier ML, Fauconnet S, Bittard H, Lascombe I. Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or-resistant malignant urothelial cells. Int J Cancer 2010; 127(8): 1769-84.
27. Sato K, Awasaki Y, Kandori H, et al. Suppressive effects of acidforming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol Appl Pharmacol 2011; 251(3): 234-44.
28. Liu S, Li Y, Lin T, Fan X, Liang Y, Heemann U. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Res Clin Pract 2011; 91(2): 177-82.
29. Metalli D, Lovat F, Tripodi F, et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt-and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol 2010; 176(6): 2997-3006.
30. McFarland MS, Cripps R. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. Parmacotherapy 2010; 30(11): 1159-78.
31. Drzewoski J, Drozdowska A, Sliwińska A. Do we have enough data to confirm the link between antidiabetic drug use and cancer development? Pol Arch Med Wewn 2011; 121(3): 81-7.
32. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylurea or insulin. Diabetes Care 2006; 29(2): 254-8.
33. Yang X, So WY, Ma RC, et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2010; 90(3): 343-51.